http://formularyjournal.modernmedicine.com/formulary Formulary provides peer-reviewed clinical information and news and drug approval updates to assist pharmacy and therapeutics committee members with their drug management responsibilities. 2010-03-18T10:28:33Z http://formularyjournal.modernmedicine.com/formulary/Combination-treatment-may-work-in-severe-acne-case/ArticleStandard/Article/detail/661122?ref=25 Adding Epiduo (adapalene and benzoyl peroxide) gel 0.1%/2.5% to doxycycline, 100 mg, may be an effective treatment for severe acne, according to results from a study sponsored by Galderma Laboratories. 2010-03-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/661122null HTML http://formularyjournal.modernmedicine.com/formulary/Ticagrelor-reduces-death-rate-in-patients-with-adu/ArticleStandard/Article/detail/661120?ref=25 Treatment with ticagrelor compared with clopidogrel in patients with acute coronary syndromes significantly reduced the death rate from vascular causes, myocardial infarction (MI), or stroke, according to the Study of Platelet Inhibition and Patient Outcomes (PLATO), a multicenter, randomized, double-blind trial. 2010-03-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/661120null HTML http://formularyjournal.modernmedicine.com/formulary/Cancer-drug-approvals-evaluated-by-government/ArticleStandard/Article/detail/661121?ref=25 More than 50 new indications for oncology and hematology drugs and biologics were cleared by the FDA?s Office of Oncology Drug Products from 2005 to 2007. 2010-03-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/661121null HTML http://formularyjournal.modernmedicine.com/formulary/Study-drug-improves-survival-for-advanced-prostate/ArticleStandard/Article/detail/661124?ref=25 Results from a Phase 3 trial by Sanofi-aventis have shown that the investigational compound, cabazitaxel, and prednisone/prednisolone markedly enhanced overall and progression-free survival in patients with metastatic hormone-refractory prostate cancer where the disease advanced after treatment with docetaxel-based chemotherapy. 2010-03-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/661124null HTML http://formularyjournal.modernmedicine.com/formulary/FDA-continues-to-closely-monitor-the-cardiovascula/ArticleStandard/Article/detail/661117?ref=25 On February 22, 2010, FDA released a safety alert reminding healthcare professionals of the agency¹s ongoing concerns regarding the cardiovascular safety of rosiglitazone (Avandia, GlaxoSmithKline). 2010-03-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/661117null HTML http://formularyjournal.modernmedicine.com/formulary/2010-Rate-Card/ArticleStandard/Article/detail/657963?ref=25 2010-02-19T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657963null PDF http://formularyjournal.modernmedicine.com/formulary/2010-Media-Kit/ArticleStandard/Article/detail/657964?ref=25 2010-02-19T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657964null PDF http://formularyjournal.modernmedicine.com/formulary/Rotavirus-vaccination-may-lessen-occurrence-of-gas/ArticleStandard/Article/detail/657003?ref=25 In the first year of a child's life, immunization with a rotavirus vaccine (Rotarix, Glaxo Smith Kline) may markedly lower incidence of severe virus gastroenteritis. 2010-02-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/657003null HTML http://formularyjournal.modernmedicine.com/formulary/Two-new-antiplatelet-agents-go-head-to-head-with-c/ArticleStandard/Article/detail/656998?ref=25 Two investigational competitors to clopidogrel took their shots against the antiplatelet giant in 3 separate randomized controlled phase 3 trials of patients undergoing percutaneous coronary intervention. 2010-02-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/656998null HTML http://formularyjournal.modernmedicine.com/formulary/Users-of-PIMs-may-be-at-risk-for-more-adverse-even/ArticleStandard/Article/detail/657001?ref=25 Older adults who take specific potentially inappropriate medications (PIMs) may raise their chances of adverse events as well as increase their healthcare costs, according to a new study. 2010-02-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/657001null HTML http://formularyjournal.modernmedicine.com/formulary/Drugs-for-orphan-diseases-seeing-more-FDA-approval/ArticleStandard/Article/detail/656996?ref=25 In the past decade, federal regulatory agencies have signed off on more new product approvals for treatment of so-called neglected diseases. 2010-02-12T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/656996null HTML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-re/ArticleStandard/Article/detail/660822?ref=25 Agents in late-stage development for renal disease 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/660822null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Cardiovascular-risk-burden-for-women-on-the-rise-w/ArticleStandard/Article/detail/657551?ref=25 Middle-aged (35 to 54 years) women are gaining ground on their male counterparts in their prevalence of myocardial infarction (MI) and their cardiovascular risk factor scores, according to an examination of the National Health and Nutrition Examination Survey (NHANES) over time. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657551null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Exenatide-LAR-A-sustained-release-formulation-of-e/ArticleStandard/Article/detail/656935?ref=25 Currently, exenatide is the only FDA-approved GLP-1 receptor agonist and its use is limited by the need for twice-daily injections. A long-acting release formulation of exenatide is being evaluated in clinical trials to assess effects on glucose control and patient quality of life. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/656935null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Disease-modifying-antirheumatic-drugs-prove-most-c/ArticleStandard/Article/detail/657557?ref=25 Therapeutic strategies involving early conventional disease-modifying antirheumatic drugs or early biologics are preferred in treating very early rheumatoid arthritis, but the additional costs of early biologics may not be justified for all patients, according to a recent study reported in the Annals of Internal Medicine. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657557null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Vigabatrin-Sabril-An-antiepileptic-drug-approved-f/ArticleStandard/Article/detail/657556?ref=25 New molecular entity: Vigabatrin (Sabril) was approved as an adjunctive treatment of refractory complex partial seizures in adults who have responded inadequately to several alternative treatments; and as monotherapy for pediatric patients with infantile spasms. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657556null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-February-2010-Ampyra-Victoza-/ArticleStandard/Article/detail/657558?ref=25 Recent FDA approvals (through February 2010) related to Ampyra, Victoza, Actemra, Tropazone, Morphine sulfate oral solution, Fluzone High-Dose 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657558null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Commissioner-Hamburg-builds-agencys-capabiliti/ArticleStandard/Article/detail/657560?ref=25 In less than 1 full year at the helm of FDA, Margaret (Peggy) Hamburg has worked to reposition FDA as a public health agency able to ensure the safety and quality of the nation's food supply and medical products. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657560null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-approvals-February-2010/ArticleStandard/Article/detail/657555?ref=25 Generic drugs approved by FDA (through February 2010): Donepezil hydrochloride orally disintegrating tablets, Ibutilide fumarate injection, Risperidone orally disintegrating tablets in 0.5-mg, 2-mg, 3-mg, and 4-mg strengths 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657555null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Approaching-the-ideal-selective-estrogen-receptor-/ArticleStandard/Article/detail/656934?ref=25 Postmenopausal osteoporosis is a worldwide health concern associated with significant complications including fracture, disability, and mortality. The economic burden of this disease is substantial and is expected to increase significantly as the population ages. It is becoming increasingly important to identify patients who will benefit from available and emerging therapies for the prevention and/or treatment of osteoporosis. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/072010/656934/FebOsteoporosisHiRes_small_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Ecallantide-Kalbitor-A-plasma-kallikrein-inhibitor/ArticleStandard/Article/detail/657547?ref=25 New molecular entity: Ecallantide (Kalbitor) was approved in December 2009, to treat hereditary angioedema (HAE). 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657547null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-finds-no-increased-cardiovascular-risk-in-pati/ArticleStandard/Article/detail/657559?ref=25 After completing a review of available tiotropium bromide inhalation powder (Spiriva HandiHaler, Pfizer) data, FDA released an updated communication, stating that in the regulatory body's opinion, available data does not support an association between the use of tiotropium, a commonly prescribed daily treatment for chronic obstructive pulmonary disease, and an increased risk of stroke, heart attack, or cardiovascular death. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657559null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-February-2010-Ceftobiprole-Ca/ArticleStandard/Article/detail/657561?ref=25 Recent FDA action (through February 2010) related to Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657561null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-February-2010/ArticleStandard/Article/detail/660821?ref=25 Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/112010/660821null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Higher-dosage-of-losartan-needed-for-maximal-benef/ArticleStandard/Article/detail/657554?ref=25 A dosage of losartan of 150 mg/day is superior to 50 mg/day for the treatment of patients with congestive heart failure (CHF). 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657554null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Low-dose-drug-combination-shows-better-outcomes-fo/ArticleStandard/Article/detail/657553?ref=25 Lenalidomide plus high-dose dexamethasone compared with lenalidomide plus low-dose dexamethasone did not result in superior time to progression, progression-free survival, or overall survival in patients with newly diagnosed myeloma, according to a recent trial. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657553null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/ER-niacin-bests-ezetimibe-on-measure-of-atheroscle/ArticleStandard/Article/detail/657552?ref=25 Extended-release niacin proved better than ezetimibe in favorably changing carotid intima-media thickness, a measure of atherosclerosis, in high-risk patients who were already receiving a statin. 2010-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/082010/657552null XML http://formularyjournal.modernmedicine.com/formulary/SSRIs-lead-to-increased-complications-including-st/ArticleStandard/Article/detail/650742?ref=25 Selective serotonin uptake inhibitors present a small but notable increased risk of stroke and death in depressed post-menopausal women, according to a new study. 2010-01-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022010/650742null HTML http://formularyjournal.modernmedicine.com/formulary/Combo-of-buproprion-and-nicotine-lozenges-may-help/ArticleStandard/Article/detail/650741?ref=25 Researchers have found that 1 in 5 smokers of at least 10 cigarettes a day will make a serious attempt to quit when offered help by health professionals and that the most effective cessation method employs a combination of bupropion SR and nicotine lozenges. 2010-01-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022010/650741null HTML http://formularyjournal.modernmedicine.com/formulary/Children-on-Medicaid-often-misdiagnosed-with-menta/ArticleStandard/Article/detail/650739?ref=25 There's a direct relationship between children using Medicaid and current and present mental health problems, according to recent federal drug research. 2010-01-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022010/650739null HTML http://formularyjournal.modernmedicine.com/formulary/US-dialysis-patients-face-higher-risk-of-drug-erro/ArticleStandard/Article/detail/650740?ref=25 Close to 20% of kidney dialysis patients have an increased chance of significant bleeding because they receive the wrong blood-clot medication after undergoing a procedure to open a blocked artery, the Journal of the American Medical Assn. reports. 2010-01-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022010/650740null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-January-2010-Testosterone-und/ArticleStandard/Article/detail/652564?ref=25 Recent FDA action (through January 2010) related to testosterone undecanoate injection, telavancin, Ampligen, doxepin, everolimus, aztreonam lysine, erlotinib, TG4010, BSI-201, midazolam, Aimspro, Motorgraft, BHR-100, dextran sulfate 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652564null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Drug-pricing-safety-access-to-dominate-agenda-in-t/ArticleStandard/Article/detail/652560?ref=25 The new team heading up FDA will be firmly established and eager to implement new policies and programs. Payers, plans, and formulary committees will be watching key trends that will shape drug development and coverage in 2010: 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652560null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Study-Prescription-patterns-and-predictors-of-aldo/ArticleStandard/Article/detail/652568?ref=25 Heart failure (HF) guideline-recommended aldosterone antagonist therapy was received by less than one-third of eligible patients participating in a quality improvement registry who had been hospitalized for HF. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652568null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Exenatide-drug-label-to-include-information-on-pos/ArticleStandard/Article/detail/652565?ref=25 In early November 2009, FDA approved revisions to the drug label for exenatide (Byetta, Amylin Pharmaceuticals), an injectable glucagon-like peptide-1 agonist for the treatment of type 2 diabetes mellitus. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652565null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Pralatrexate-injection-Folotyn-Folate-analogue-met/ArticleStandard/Article/detail/652561?ref=25 New molecular entity: Pralatrexate injection (Folotyn) was approved on September 24, 2009, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652561null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Erectile-dysfunction-and-premature-ejaculation-und/ArticleStandard/Article/detail/652562?ref=25 This review examines the underlying causes associated with ED and PE and evaluates currently available treatment options and those under investigation. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652562/EDHiRes[1]_small_flash_thumbnail.jpg XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Anticoagulants-and-antiplatelet-agents-/ArticleStandard/Article/detail/653054?ref=25 Anticoagulants and antiplatelet agents in late-stage development 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/653054null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Roflumilast-A-new-phosphodiesterase-4-inhibitor-fo/ArticleStandard/Article/detail/652566?ref=25 Roflumilast is a novel, orally active phosphodiesterase 4 inhibitor currently under review by FDA for the treatment of patients with moderate-to-severe COPD. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652566null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Dabigatran-compared-to-warfarin-when-given-to-pati/ArticleStandard/Article/detail/652558?ref=25 Dabigatran, a new oral direct thrombin inhibitor, given to patients with atrial fibrillation at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652558null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Diclofenac-sodium-topical-solution-Pennsaid-Nonste/ArticleStandard/Article/detail/652567?ref=25 New formulation: Diclofenac sodium topical solution (Pennsaid) was approved on November 5, 2009, to treat the signs and symptoms of osteoarthritis of the knee. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652567null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/ACE-inhibitors-versus-ARBs-for-ischemic-heart-dise/ArticleStandard/Article/detail/652563?ref=25 A systematic review into the comparative effectiveness of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), or both, for patients with stable ischemic heart disease and preserved left ventricular (LV) function found that adding an ACE inhibitor to standard treatment can improve outcomes. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652563null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-January-2010/ArticleStandard/Article/detail/652809?ref=25 Erectile dysfunction and premature ejaculation: underlying causes and available treatments; Focus on roflumilast; Anticoagulants and antiplatelet agents in late-stage development 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652809null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-approvals-January-2010/ArticleStandard/Article/detail/652559?ref=25 Generic drugs approved by FDA (through January 2010): Nizatidine oral solution in the 15 mg/mL strength 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652559null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-January-2010-Cymbalta-Zyprexa/ArticleStandard/Article/detail/652557?ref=25 Recent FDA approvals (through January 2010) related to Cymbalta, Zyprexa, Zyprexa Relprevv, Intelence, Kalbitor, Istodax, Geodon, Vagifem, Seroquel XR, Clonidine ER Suspension, Clonidine ER Tablets, Wilate 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652557null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDAs-Safe-Use-Initiative-to-address-preventable-ha/ArticleStandard/Article/detail/652569?ref=25 Towards the end of 2009, FDA launched a new medication safety initiative. 2010-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652569null XML http://formularyjournal.modernmedicine.com/formulary/No-change-in-FDA-approval-time-despite-new-technol/ArticleStandard/Article/detail/647207?ref=25 Even given implementation of information technology, FDA drug approval time has not decreased, according to researchers. 2009-12-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647207null HTML http://formularyjournal.modernmedicine.com/formulary/IDSA-requests-10-new-antibiotics-by-2020/ArticleStandard/Article/detail/647206?ref=25 The Infectious Diseases Society of America (IDSA) is calling for development of 10 new antibiotics by 2020 2009-12-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647206null HTML http://formularyjournal.modernmedicine.com/formulary/Hyperlipidemia+Top+Story/Statin-use-lowers-risk-of-gallstones-followed-by-c/ArticleStandard/Article/detail/647209?ref=25 Use of statins over a long period of time was associated with a decreased risk of gallstones followed by cholecystectomy. 2009-12-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647209null HTML http://formularyjournal.modernmedicine.com/formulary/Some-fertility-drugs-pose-slight-risk-of-cancer-ba/ArticleStandard/Article/detail/647208?ref=25 Use of fertility drugs does not seem to generally increase uterine cancer risk, however, a Danish study identified small increases in risk from certain fertility drugs used for a longer period. 2009-12-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647208null HTML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-December-2009/ArticleStandard/Article/detail/652721?ref=25 Fibromyalgia: A review of management options; Focus on eslicarbazepine acetate; Agents in late-stage development for the treatment of orphan diseases 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652721null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-December-2009-Denosumab-Binod/ArticleStandard/Article/detail/647908?ref=25 Recent FDA action (through Dec 2009) related to denosumab, binodenoson, toremifene 80 mg, zolpidem tartrate sublingual tablet, QAB149, raxibacumab, rituximab, pneumococcal 13-valent conjugate vaccine, velaglucerase alfa, sirolimus ophthalmic injection, custirsen, GSK-3 inhibitor, aztreonam for inhalation solution, rosuvastatin calcium tablets 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647908null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Eslicarbazepine-A-novel-antiepileptic-agent-design/ArticleStandard/Article/detail/647914?ref=25 Eslicarbazepine acetate (eslicarbazepine, or ESL) is a new antiepileptic agent awaiting FDA approval. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647914null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Telmisartanamlodipine-Twynsta-approved-for-high-bl/ArticleStandard/Article/detail/647913?ref=25 New combination: Telmisartan/amlodipine (Twynsta) was approved on October 16, 2009, for high blood pressure. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647913null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Telmisartan-Micardis-Angiotensin-II-receptor-block/ArticleStandard/Article/detail/647910?ref=25 New indication: Telmisartan tablets (Micardis) was approved on October 19, 2009, for cardiovascular risk reduction for patients unable to take an ACE inhibitor. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647910null XML http://contemporarypediatrics.modernmedicine.com/contpeds/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/648249?ref=25 Agents in late-stage development for the treatment of orphan diseases. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512009/648249null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Fibromyalgia-A-review-of-management-options/ArticleStandard/Article/detail/647907?ref=25 Evidence-based recommendations utilize an integrated approach that combines nonpharmacologic approaches (specifically patient education, exercise, and cognitive behavioral therapy) and pharmacologic approaches in the management of fibromyalgia. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647907/Fibromyalgia_DEC_COVER_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-approvals-December-2009/ArticleStandard/Article/detail/647912?ref=25 Generic drugs approved by FDA (through December 2009): Lansoprazole 15 mg and 30 mg tablets and Perindopril erbumine tablets, 2 mg, 4 mg, and 8 mg 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647912null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-December-2009-Zirgan-Welchol-/ArticleStandard/Article/detail/647911?ref=25 Recent FDA approvals (through December 2009) related to Zirgan, Welchol, Sculptra Aesthetic, Berinert, Crestor, Agriflu, and Byetta. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647911null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Generic-drugs-dominate-market-look-to-expand-into-/ArticleStandard/Article/detail/647909?ref=25 Generics makers have aggressively challenged drug patents before scheduled expiration, while brand-name manufacturers have delayed generic entry through 30-month stays, citizen petitions, and deals to "authorize" generic products that are less threatening to the brand. 2009-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502009/647909null XML http://formularyjournal.modernmedicine.com/formulary/Rare-strain-of-S-Aureus-is-found-to-be-the-deadlie/ArticleStandard/Article/detail/640877?ref=25 USA600, a rare strain of drug-resistant Staphylococcus aureus is about 5 times more deadly than other strains, according to a study at Henry Ford Hospital in Detroit. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640877null HTML http://formularyjournal.modernmedicine.com/formulary/Statins-improve-H1N1-survival/ArticleStandard/Article/detail/640910?ref=25 Hospitalized patients with the seasonal flu who were taking statins were twice as likely to survive than those who weren't taking the drug. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640910null HTML http://formularyjournal.modernmedicine.com/formulary/FDA-initiative-announced-to-reduce-preventable-har/ArticleStandard/Article/detail/640873?ref=25 FDA announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640873null HTML http://formularyjournal.modernmedicine.com/formulary/Statins-may-have-negative-effect-on-some-cardiac-p/ArticleStandard/Article/detail/640907?ref=25 Statins may have negative effects on some cardiac patients, according to a study presented at CHEST 2009. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640907null HTML http://formularyjournal.modernmedicine.com/formulary/Some-antibiotics-tied-to-birth-defects/ArticleStandard/Article/detail/640876?ref=25 Researchers studying the association between birth defects and antibiotics use early in pregnancy-1 month before through the third month-have found a link between common drugs used to treat urinary infections with birth defects. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640876null HTML http://formularyjournal.modernmedicine.com/formulary/NSAIDs-reduce-mortality-in-colorectal-cancer/ArticleStandard/Article/detail/640903?ref=25 Prediagnosis regular nonsteroidal anti-inflammatory drug (NSAID) use and prolonged duration of NSAID use were independently associated with decreased overall mortality and colorectal cancer (CRC) mortality in women with a first primary invasive CRC, according to a large cohort study. 2009-11-11T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/462009/640903null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Safety-concerns-slow-new-drug-review-and-approval-/ArticleStandard/Article/detail/640136?ref=25 FDA is struggling to implement a host of new drug safety policies and programs and still meet review time frames set by the Prescription Drug User Fee program (PDUFA). 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640136null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Thiopurines-increase-lymphoproliferative-disorder-/ArticleStandard/Article/detail/640139?ref=25 Patients with inflammatory bowel disease receiving thiopurines are at increased risk of developing lymphoproliferative disorder, according to a French prospective observational cohort study, which was published online in The Lancet. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640139null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Travoprost-A-prostaglandin-analogue-for-the-treatm/ArticleStandard/Article/detail/640137?ref=25 In August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640137null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-November-2009-FluMist-Cervari/ArticleStandard/Article/detail/640132?ref=25 Recent FDA approvals (through November 2009) related to FluMist, Cervarix, Gardasil, Fluarix, Folotyn, Micardis, Twynsta, Votrient, Mirena 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640132null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Ustekinumab-Stelara-First-in-class-human-monoclona/ArticleStandard/Article/detail/640142?ref=25 New biologic: Ustekinumab (Stelara) was approved on September 25, 2009, for the treatment of adult patients aged 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640142null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/644639?ref=25 Agents in late-stage development for the treatment of gastrointestinal disorders 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/492009/644639null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-October-2009-Eplivanserin-Pan/ArticleStandard/Article/detail/640134?ref=25 Recent FDA action (through November 2009) related to Eplivanserin, Pancrelipase, Trabectedin, Clofarabine, Fampridine-SR, Collagenase clostridium histolyticum, Oxycodone reformulated, Pegylated interferon alfa-2b, Maraviroc, Armodafinil, Relaxin, Perifosine, Glycerol phenylbutyrate, Trabedersen. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640134null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Two-antimalaria-drugs-are-tolerated-regimens-in-re/ArticleStandard/Article/detail/640133?ref=25 In a review published in The Cochrane Library, researchers determined that atovaquone-proguanil and doxycycline were well tolerated by most travelers and are less likely than mefloquine to cause adverse neuropsychiatric outcomes. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640133null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bloodstream-infections-and-contaminated-prefilled-/ArticleStandard/Article/detail/640140?ref=25 An investigation into a multistate outbreak of Serratia marcescens bloodstream infections (BSIs) published in the Archives of Internal Medicine found an association between the BSIs and contamination of prefilled syringes. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640140null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Development-of-an-adverse-drug-reaction-bulletin-i/ArticleStandard/Article/detail/640135?ref=25 Bulletins that focus on drugs and therapeutic matters are often distributed by hospitals and other health systems that have programs for reporting adverse drug reactions. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640135null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-November-2009/ArticleStandard/Article/detail/652715?ref=25 Focus on 2009: A year of novel pharmacologic agents in review; Focus on travoprost; Agents in late-stage development for the treatment of gastrointestinal disorders 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652715null REMOTE http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Valsartan-and-aliskiren-Valturna-Combination-of-an/ArticleStandard/Article/detail/640138?ref=25 New combination: Valturna was approved on September 16, 2009, for the treatment of hypertension in patients not adequately controlled on either aliskiren or angiotensin receptor blocker monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640138null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Focus-on-2009-A-year-of-novel-pharmacologic-agents/ArticleStandard/Article/detail/640141?ref=25 This article reviews the 10 newly improved or investigational agents evaluated in this year's "Focus on" column and includes an update on the regulatory status of each drug. 2009-11-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/452009/640141/Form_cvrArt_1109_200x190[1]_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Three-diet-drugs-in-final-stages-of-research-and-d/ArticleStandard/Article/detail/637892?ref=25 Three prescription diet drugs are in the final stages of development. According to USA Today, the drugs' manufacturers still have to submit their new drug applications to FDA and go through a rigorous review and approval process. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637892null HTML http://formularyjournal.modernmedicine.com/formulary/Comparative-effectiveness-research-could-threaten-/ArticleStandard/Article/detail/637890?ref=25 The federal government?s push to control health costs through comparative effectiveness research could threaten strides in personalized medicine, in which medicines are tailored to an individual?s genetic makeup, said the National Institutes of Health chief at a recent forum sponsored by the American Association for the Advancement of Science. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637890null HTML http://formularyjournal.modernmedicine.com/formulary/Study-results-show-risk-factors-for-ulcer-developm/ArticleStandard/Article/detail/637893?ref=25 Horizon Therapeutics Inc., a privately held biopharmaceutical company, recently presented an analysis from 2 pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine, PRNewswire reports. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637893null HTML http://formularyjournal.modernmedicine.com/formulary/Long-acting-once-a-day-insulin-dose-may-be-best-fo/ArticleStandard/Article/detail/637897?ref=25 Adding insulin to standard diabetes drugs results in better blood sugar control for many with type-2 diabetes, and the dose and timing of insulin received can make a big difference, British researchers report. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637897null HTML http://formularyjournal.modernmedicine.com/formulary/Statin-drugs-may-increase-diabetes-risk/ArticleStandard/Article/detail/637911?ref=25 Cholesterol-lowering statin drugs do not reduce the risk of diabetes and might modestly elevate the chances of developing the condition, researchers found in a pooled analysis of trial data. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637911null HTML http://formularyjournal.modernmedicine.com/formulary/New-antipsychotics-lead-to-weight-gain-in-young-pa/ArticleStandard/Article/detail/637909?ref=25 Atypical antipsychotic agents lead to a marked and rapid weight gain in children and adolescents, according to researchers at Zucker Hillside Hospital in Glen Oaks, NY and the Albert Einstein College of Medicine, NY. 2009-10-29T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/637909null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Telavancin-for-injection-Vibativ-Lipoglycopeptide-/ArticleStandard/Article/detail/636925?ref=25 New molecular entity: Telavancin for injection (Vibativ) was approved on September 11, 2009, for the treatment of complicated skin and skin-structure infections (cSSSIs) 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636925null XML http://formularyjournal.modernmedicine.com/formulary/Formulary-Digital-Edition-October-2009/ArticleStandard/Article/detail/652716?ref=25 Specialty pharmacy's role in REMS, FDA's new drug safety program; Focus on Fampridine-SR; FDA leadership promotes scientific integrity, quality standards 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042010/652716null REMOTE http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Agents-in-late-stage-development-for-th/ArticleStandard/Article/detail/630977?ref=25 Agents in late-stage development for the treatment of mixed dyslipidemia, coronary heart disease, atherosclerosis, and hypertension 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/402009/630977null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/First-time-generic-drug-approvals-October-2009/ArticleStandard/Article/detail/636928?ref=25 Generic drugs approved by FDA (through October 2009): 1% clindamycin/5% benzoyl peroxide gel, triamcinolone acetonide nasal spray, clonidine transdermal system, betamethasone acetate and betamathasone sodium phosphate injectable suspension 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636928null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Fampridine-SR-A-potassium-channel-blocker-for-the-/ArticleStandard/Article/detail/636929?ref=25 Fampridine-SR is a sustained-release oral medication that is pending FDA approval for the symptomatic treatment of multiple sclerosis (MS). 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636929null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Guanfacine-extended-release-tablets-Intuniv-Select/ArticleStandard/Article/detail/636926?ref=25 New formulation: Guanfacine extended-release tablets (Intuniv) were approved on September 2, 2009, for the treatment of attention-deficit/hyperactivity disorder (ADHD) 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636926null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Specialty-pharmacys-role-in-REMS-FDAs-new-drug-saf/ArticleStandard/Article/detail/636927?ref=25 Specialty pharmacies are uniquely positioned to play a key role in the implementation of Risk Evaluation and Mitigation Strategies (REMS). 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636927/REMSSpecialty_flash.gif XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-leadership-promotes-scientific-integrity-quali/ArticleStandard/Article/detail/636932?ref=25 FDA officials are taking steps to erase the charges of incompetency and ineffectiveness that have plagued the agency for several years. 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636932null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-actions-in-brief-October-2009-Sabril-Helixate-/ArticleStandard/Article/detail/636933?ref=25 Recent FDA approvals (through October 2009) related to Sabril, Helixate FS, Valcyte, Metozolv ODT, Xyzal, Zevalin, Extavia, Astepro, Zenpep, and Bepreve 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636933null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-preview-October-2009-doxorubicin-trab/ArticleStandard/Article/detail/636930?ref=25 Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636930null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Morphinenaltrexone-extended-release-capsules-Embed/ArticleStandard/Article/detail/636931?ref=25 New combination: Morphine/naltrexone extended-release capsules (Embeda) were approved on August 13, 2009, for the management of moderate-to-severe pain when continuous analgesia is needed for an extended time period 2009-10-01T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/442009/636931null XML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/Medication-interventions-get-a-boost-from-a-powerf/ArticleStandard/Article/detail/626170?ref=25 Pharmacists can improve patient outcomes by following 3 major functions: identification of potential and actual medication-related problems (MRPs), resolution of actual MRPs, and prevention of potential MRPs. The best way to achieve these goals is through accurate documentation, and one of the chief obstacles to this is time?or rather the lack of it. Various software programs have been developed to help pharmacists reduce time spent identifying opportunities for interventions. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626170null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Perioperative-fluvastatin-treatment-associated-wit/ArticleStandard/Article/detail/626135?ref=25 In the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography III (DECREASE III) trial published in the New England Journal of Medicine, patients undergoing noncardiac vascular surgery who were treated with perioperative fluvastatin demonstrated a lower incidence of myocardial ischemia than patients treated with placebo. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626135null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-issues-early-communication-about-ongoing-safet/ArticleStandard/Article/detail/626174?ref=25 FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626174null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Leukotriene-inhibitors-associated-with-neuropsychi/ArticleStandard/Article/detail/626175?ref=25 In an update to an earlier communication, FDA announced that the manufacturers of the leukotriene inhibitors montelukast (Singular), zafirlukast (Accolate), zileuton (Zyflo), and zileuton extended-release (Zyflo CR) are adding information about neuropsychiatric events to product labeling. 2009-09-14T04:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382009/626175null HTML